Mineralys Therapeutics (MLYS) Long-Term Investments (2023)
Mineralys Therapeutics' (MLYS) quarterly Long-Term Investments came in at $2.5 million in Q4 2023, down 79.54% quarter-over-quarter from $12.1 million in Q3 2023.
Mineralys Therapeutics (MLYS) Long-Term Investments (2023) Analysis & Trends
Mineralys Therapeutics has disclosed Long-Term Investments across 1 years of filings, most recently posting $2.5 million for Q4 2023.
- Long-Term Investments for Q4 2023 came in at $2.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $2.5 million (changed N/A YoY), and the FY2023 annual result was $2.5 million, changed N/A from the prior year.
- Long-Term Investments came in at $2.5 million for Q4 2023 at Mineralys Therapeutics, down from $12.1 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $31.1 million in Q1 2023 to a low of $2.5 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Mineralys Therapeutics | 1.95 Bn | 1.95 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 2.48 Mn |
| Sep 30, 2023 | 12.13 Mn |
| Jun 30, 2023 | 21.68 Mn |
| Mar 31, 2023 | 31.12 Mn |